Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock

Platelets

Volumn 24, Issue 6, 2013, Pages 480-485

  Otto, Gordon Philipp ^a   Sossdorf, Maik ^a   Boettel, Janina ^a   Kabisch, Björn ^a   Breuel, Hannes ^a   Winning, Johannes ^a   Lösche, Wolfgang ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Acetylsalicylic acid; Cardiovascular disease; Platelets; Sepsis; Sepsis therapy

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROCALCITONIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CALCITONIN BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG EFFECT; DRUG EFFICACY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SECONDARY PREVENTION; SEPSIS; SEPTIC SHOCK; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 84880852776     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.724482     Document Type: Article

References (43)

1. Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie 2011;30:10-12, 14-16.
2. Tyml K. Critical role for oxidative stress, platelets, and coagulation in capillary blood flow impairment in sepsis. Microcirculation 2011;18:152-62.
3. Esmon CT, Fukudome K, Mather T, Bode W, Regan LM, Stearns-Kurosawa DJ, Kurosawa S. Inflammation, sepsis, and coagulation. Haematologica 1999;84:254-259.
4. Russwurm S, Vickers J, Meier-Hellmann A, Bredl D, Spangenberg P, Reinhart K, Lösche W. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 2002;17:263-268.
5. Bockmeyer CL, Reuken PA, Simon TP, Budde U, Losche W, Bauer M, Birschmann I, Becker JU, Marx G, Claus RA. ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus deposition. Thromb Haemost 2011;105:145-153.
6. Levi M, Schultz M. Coagulopathy and platelet disorders in critically ill patients. Minerva Anestesiol 2010;76:851-859.
7. Akca S, Haji-Michael P, de Mendonca A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med 2002;30:753-756.
8. Moreau D, Timsit JF, Vesin A, Garrouste-Orgeas M, de Lassence A, Zahar JR, Adrie C, Vincent F, Cohen Y, Schlemmer B, et al. Platelet count decline: An early prognostic marker in critically ill patients with prolonged ICU stays. Chest 2007;131:1735-1741.
9. Vandijck DM, Blot SI, De Waele JJ, Hoste EA, Vandewoude KH, Decruyenaere JM. Thrombocytopenia and outcome in critically ill patients with bloodstream infection. Heart Lung 2010; 39:21-26.
10. Winning J, Neumann J, Kohl M, Claus RA, Reinhart K, Bauer M, Lösche W. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 2010;38:32-37.
11. Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, Claus RA, Bauer M, Lösche W. Anti-platelet drugs and outcome in severe infection: Clinical impact and underlying mechanisms. Platelets 2009;20:50-57.
12. Eisen DP, Reid D, McBryde ES. Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit Care Med 2012;40: 1761-1767.
13. Erlich JM, Talmor DS, Cartin-Ceba R, Gajic O, Kor DJ. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: A population-based cohort study. Chest 2011;139:289-295.
14. Kor DJ, Erlich J, Gong MN, Malinchoc M, Carter RE, Gajic O, Talmor D. Association of prehospitalization aspirin therapy and acute lung injury: Results of a multicenter international observational study of at-risk patients. Crit Care Med 2011;39: 2393-2400.
15. Hagiwara S, Iwasaka H, Hasegawa A, Oyama M, Imatomi R, Uchida T, Noguchi T. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock 2011;35:289-292.
16. Seidel M, Winning J, Claus RA, Bauer M, Losche W. Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis. J Thromb Haemost 2009;7:1030-1032.
17. Pu Q, Wiel E, Corseaux D, Bordet R, Azrin MA, Ezekowitz MD, Lund N, Jude B, Vallet B. Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endothelium in Escherichia coli endotoxin-induced shock. Crit Care Med 2001;29:1181-1188.
18. Taylor FB, Coller BS, Chang AC, Peer G, Jordan R, Engellener W, Esmon CT. 7E3 F(ab')2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli. Blood 1997;89: 4078-4084.
19. Walther A, Czabanka M, Gebhard MM, Martin E. Glycoprotein IIB/IIIA-inhibition and microcirculatory alterations during experimental endotoxemia - An intravital microscopic study in the rat. Microcirculation 2004;11:79-88.
20. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: Impact of aspirin and statins. Circ Res 2010;107:1170-1184.
21. Prescott D, McKay DM. Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am J Physiol Gastrointest Liver Physiol 2011;301:G487-G497.
22. Wang YP, Wu Y, Li LY, Zheng J, Liu RG, Zhou JP, Yuan SY, Shang Y, Yao SL. Aspirin-triggered lipoxin A4 attenuates LPSinduced pro-inflammatory responses by inhibiting activation of NF-kappaB and MAPKs in BV-2 microglial cells. J Neuroinflammation 2011;8:95.
23. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002;252:283-294.
24. Steffens S, Mach F. Inflammation and atherosclerosis. Herz 2004;29:741-748.
25. Vardavas CI, Panagiotakos DB. The causal relationship between passive smoking and inflammation on the development of cardiovascular disease: A review of the evidence. Inflamm Allergy Drug Targets 2009;8:328-333.
26. Ikonomidis I, Michalakeas CA, Lekakis J, Parissis J, Anastasiou-Nana M. The role of lipoprotein-associated phospholipase A2 (Lp-PLA) in cardiovascular disease. Rev Recent Clin Trials 2011;6:108-113.
27. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 2008;26:711-715.
28. Giamarellos-Bourboulis EJ. What is the pathophysiology of the septic host upon admissioñ Int J Antimicrob Agents 2010;36(Suppl 2):S2-S5.
29. Christensen S, Thomsen RW, Johansen MB, Pedersen L, Jensen R, Larsen KM, Larsson A, Tonnesen E, Sorensen HT. Preadmission statin use and one-year mortality among patients in intensive care - A cohort study. Crit Care 2010;14:R29.
30. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J. The effect of statins on mortality from severe infections and sepsis: A systematic review and meta-analysis. J Crit Care 2010;25:656 e7-e22.
31. Kouroumichakis I, Papanas N, Proikaki S, Zarogoulidis P, Maltezos E. Statins in prevention and treatment of severe sepsis and septic shock. Eur J Intern Med 2011;22:125-133.
32. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-1655.
33. Rangel-Frausto MS. Sepsis: Still going strong. Arch Med Res 2005;36:672-681.
34. Marshall JC, Vincent JL, Fink MP, Cook DJ, Rubenfeld G, Foster D, Fisher Jr. CJ, Faist E, Reinhart K. Measures, markers, and mediators: Toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 2003;31: 1560-1567.
35. Johansson D, Shannon O, Rasmussen M. Platelet and neutrophil responses to Gram positive pathogens in patients with bacteremic infection. PLoS One 2011;6:e26928.
36. Ziegelstein RC, Green A, Sauder M. Dual antiplatelet therapy and the risk of bleeding. Arch Intern Med 2011;171:787.
37. Bolognese L, Angiolillo DJ. Unravelling the benefit against the risk of long-term dual antiplatelet therapy. Curr Opin Cardiol 2011;26(Suppl 1):S22-S30.
38. Goodin J, Manrique C, Dulohery M, Sampson J, Saettele M, Dabbagh O. Effect of statins on the clinical outcomes of patients with sepsis. Anaesth Intensive Care 2011;39:1051-1055.
39. Piechota M, Barylski M, Hannam S, Piechota-Urbanska M, Banach M. Rationale of statin therapy in septic patients. Curr Vasc Pharmacol 2012, Jan 20 [Ebup ahead of print].
40. Aydemir H, Piskin N, Akduman D, Kokturk F, Aktas A. Platelet and mean platelet volume kinetics in adult patients with sepsis. Platelets. doi/abs/10.3109/09537104.2012.701027, 2012 June 25 [Epub ahead of print].
41. Eisen DP. Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis. Intensive Care Med 2012;38:1249-1257.
42. O'Neal Jr. HR, Koyama T, Koehler EA, Siew E, Curtis BR, Fremont RD, May AK, Bernard GR, Ware LB. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 2011;39:1343-1350.
43. Sanchez MA, Thomas CB, O'Neal HR. Do aspirin and statins prevent severe sepsis? Curr Opin Infect Dis 2012;25:345-350.